EUCTR2011-000099-33-NL进行中(未招募)不适用
The Metformin in CABG (MetCAB) trial - MetCAB trial
Radboud University Nijmegen Medical Centre0 个研究点目标入组 110 人开始时间: 2011年5月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Acceptation for CABG
- •- Informed consent
- •- Age = 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •-Diabetes mellitus
- •-Renal dysfunction (MDRD < 60 ml/min)
- •-Elevated liver enzymes (ALAT > 3 times upper limit of reference range)
- •-Treatment with dipyridamole or xanthine derivatives
- •-Recent myocardial infarction (<2 weeks before inclusion)
研究者
相似试验
进行中(未招募)
1 期
A study of the effects of oxytocin and carbetocin on the heartPregnancyMedDRA version: 17.0Level: SOCClassification code 10036585Term: Pregnancy, puerperium and perinatal conditionsSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 17.0Level: LLTClassification code 10048862Term: Cesarean sectionSystem Organ Class: 100000004865EUCTR2014-000507-27-NOOslo University Hospital, Division of Emergencies and Critical Care
进行中(未招募)
2 期
Phase II study of 4-drug combination chemotherapy in patients with non-small cell lung cancer harboring EGFR active mutation.on-small cell lung cancerJPRN-jRCTs031180157Kurata Takayasu35
已完成
2 期
Phase II study of combination chemotherapy of Carboplatin, Pemetrexed, Bevacizumab and Erlotinib in patients with advanced non-squamous non-small cell lung cancer harboring EGFR active mutation.JPRN-UMIN000029476orth East Japan Study Group (NEJSG)16
尚未招募
4 期
TO STUDY THE EFFECT OF BARYTA CARBONICA AS A CHILDRENS REMEDYCTRI/2024/02/063030Shamini J S
已完成
1 期
Capecitabine and erlotinib in advanced lung cancerCancerISRCTN18199864Royal Marsden NHS Foundation Trust40
